Resources
Opiant donates to organizations supporting patients vulnerable to substance use disorders during COVID-19
Opiant donated $40,000 to the International Association of Fire Fighters Foundation, the Association of Recovery in Higher Education, the Harm Reduction Coalition and the UK’s Action on Addiction.
Lessons from a doctor and CEO on the US’s opioid crisis
April 14, 2020 – Roger Crystal set out to impact healthcare at a ‘societal’ level. The doctor who developed the NARCAN® Nasal Spray says he is proud to see its impact on the opioid crisis in the United States: the opioid overdose reversal medicine has saved a large number of lives.
Cannabinoid1 (CB‐1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Published in 2020 by the Journal of Neural Transmission.
Fighting the Opioid Crisis – FOX Business
October 21, 2019 – Opiant CEO Roger Crystal on The Claman Countdown discusses the fight on the opioid crisis.
Opioid Crisis: Could It Have Been Prevented? – Stateside i24News
August 21, 2019 – Opiant CEO Roger Crystal on Stateside i24News discusses the fight on the opioid crisis.
Battling Opioid Abuse – KTVU-TV
August 19, 2019 – Opiant CEO Dr. Roger Crystal discusses fighting opioid abuse with NARCAN®.
Combating America’s Opioid Crisis – Fox & Friends
April 11, 2019 – Opiant CEO Dr. Roger Crystal discusses treating opioid addiction with marijuana.
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Published in March 2019 by American College of Neuropsychopharmacology.
Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose
Published in 2019 by the Journal of Clinical Pharmacology.